The NAD+ You've Already Lost

Here's a number you'll see quoted on a hundred supplement labels: NAD+ levels fall by about half between your twenties and your fifties. It's a striking figure, and it's roughly true, and almost everyone who repeats it gets the meaning wrong in one of two directions. Either they treat it as a death sentence, or they treat it as a problem you can buy your way out of by Tuesday. Both are wrong. The truth sits in a more interesting middle, and it's worth getting right, because this molecule is doing more on the court than you probably realize.

What NAD+ is, in one paragraph

NAD+ — nicotinamide adenine dinucleotide — is a coenzyme present in every cell you own. Its day job is shuttling electrons through the reactions that turn food and oxygen into ATP, the energy currency your muscles spend on every shot. We've described that role in why your third game feels different, because the third-game fade is partly a story about NAD+ running short under load. But energy is only half of it. NAD+ is also the substrate — the consumable raw material — for a family of repair and regulatory enzymes, including the sirtuins and the PARPs, that handle DNA maintenance, stress response, and a great deal of the cellular housekeeping that keeps tissue functioning over time. It is, in other words, both fuel-handler and repair-crew supply. That's why its decline shows up everywhere at once.

Where the 50% comes from

The figure traces back to a body of measurement work — in tissues, in skin, in various cell types — showing that NAD+ concentrations are markedly lower in older adults than in younger ones. The exact slope varies by tissue and by study, and honesty requires saying so: this isn't a single clean line measured in one person across forty years. It's a composite drawn from many measurements, and the "50% by your fifties" shorthand smooths over real variation. But the direction is not in dispute. NAD+ goes down with age. The disagreement is about pace and mechanism, not fact.

Why does it fall? Two forces, pulling together. Production drifts down — the enzymatic machinery that synthesizes NAD+ becomes less efficient, and the supply of precursors changes. And consumption climbs. As we accumulate the ordinary cellular wear of decades, the PARP repair enzymes get busier, and busier PARPs burn through more NAD+. So you have a supply line slowing and a demand line rising at the same time. The gap between them is the decline. It's not that your cells stopped wanting NAD+. It's that they're spending more of it on repair while making less of it overall.

Why the curve bends downward

It's worth sitting with the why a moment longer, because the mechanism tells you which levers exist.

Take consumption first. As cells age, they accumulate the ordinary insults of living — oxidative stress, the occasional nick in a strand of DNA, the metabolic debris of decades. The PARP enzymes that handle DNA repair respond to that accumulation by working harder, and PARPs are voracious NAD+ consumers; every repair they perform spends the molecule. So the more wear a cell has logged, the more of its NAD+ goes to maintenance rather than to energy. Aging cells are, in a sense, running a larger and larger repair bill out of the same shrinking account.

Now production. There's evidence that a key enzyme early in the salvage pathway becomes less abundant or less efficient with age, which throttles the rate at which the loop can regenerate NAD+ from its recycled parts. Pair a slowing supply line with a rising repair bill and you get a deficit that widens not because of any single dramatic failure but because two ordinary trends point the same direction. That's the unsettling elegance of it. Nothing breaks. The accounting just slowly turns against you.

This framing matters because it tells you where intervention could even theoretically help. You can't easily un-age the enzymes. But you can reduce the wear that drives consumption — through sleep, through not over-training into chronic inflammation — and you can, at least in principle, supply more raw material to a salvage loop that's running short. Which is the entire premise the precursor research is testing.

What it actually feels like on court

Translate that into a Saturday morning. A twenty-eight-year-old and a fifty-six-year-old play the same three games. They burn ATP at comparable rates during the rallies. But the younger player is resynthesizing it against a fuller NAD+ reserve, and crucially, recovering between points and between games against that fuller reserve too. The older player isn't weaker in the muscle. The reserve is just thinner, so the resupply runs closer to the edge, and the edge arrives sooner.

You feel it as the third game. You feel it as the morning after — the stiffness that lingers a day longer than it used to, the session that takes two days to bounce back from instead of one. That lingering is, in part, the repair crew working against a smaller stockpile. The work still gets done. It just gets done more slowly, which is exactly what aging is when you look at it up close: not collapse, but a slower return to baseline. We've made the case that next-day readiness is the metric worth watching, and the NAD+ decline is a big part of why that metric drifts.

What the number does not mean

Now the necessary cold water, because this is where the marketing gets dishonest.

First: lower NAD+ at fifty does not mean you're broken. Plenty of people in their sixties and seventies play extraordinary pickleball — we spent a weekend in Naples with eight of them — on a NAD+ baseline well below their younger selves'. The decline is real and it's also survivable, trainable-around, and partly modifiable. A diminished reserve is a constraint, not a verdict.

Second: raising a number on a lab assay is not the same as improving how you play, and anyone collapsing the two is selling you the gap between them. The research on supplementing NAD+ precursors in humans is genuinely active and genuinely promising — studies have shown that oral precursors can raise circulating NAD+ markers. But "raises a blood marker" and "you recover a day faster from a tournament" are different claims with different evidence behind them, and the second one is far from settled. We lay out where the science is firm and where it's still open on the science page, and we'd rather under-promise there than insult you.

Third: the decline is not uniform or fixed. Exercise itself — the very pickleball you're worried about — appears to support the NAD+ system. Sleep matters enormously. So the decline curve isn't a fixed line you helplessly slide down. It's a curve with inputs, some of which are in your hands every single day.

The useful takeaway

The honest framing is this. By your fifties, you are almost certainly working with substantially less NAD+ than you had at thirty. That's a real constraint, and it explains a great deal of what's changed in your recovery and your late-session stamina. It is not, however, an expiration date, and the people who play best deep into later life are not the ones with the most NAD+ — they're the ones managing the constraint most intelligently, through the unglamorous levers of sleep, training, and consistency.

Whether topping up precursors helps you specifically is a question for a ninety-day experiment and a conversation with your physician, not a label. The number — fifty percent by fifty — is a useful piece of self-knowledge. Treat it as a map of the terrain, not a sentence handed down. The terrain is steeper than it was at thirty. You can still climb it for a very long time.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before beginning any supplement, especially if pregnant, nursing, or taking medication.